MRNA · Moderna Inc.
The AI's read
Moderna and Merck reported interim INTerpath-001 results that improved recurrence-free and distant metastasis-free survival versus Keytruda, and William Blair upgraded Moderna, sharply raising approval odds and revenue assumptions. The analyst now models multibillion-dollar peak sales across melanoma, NSCLC, and RCC and assumes high pricing. The headline already produced a huge run earlier—MRNA spiked about 170%—so much upside looks priced into the move. Price action then ripped and reversed, with the stock down roughly 20% intraday, which smells like sell-the-news and headline volatility. Bottom line: clinical data and an upgrade are bullish for the program but the market has likely front-loaded expectations. We lean neutral until confirmatory reads and clearer commercial timing reduce binary risk.